Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.

LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet Infectious Diseases published results from the company's OVX836-003 study under the title, “Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomised, double-blind placebo-controlled, Phase 2a trial.” The research.

Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836

Spectrum stockholders will receive contingent value rights, too, along with Assertio shares. The rewards are payable on achievement of 2024 and 2025 sales levels from Spectrum's lead drug. Rolvedon has already reached the first (hardest) target in Q1 without the help of a J-Code that took effect at the beginning of Q2.

Buy Spectrum Pharmaceuticals For Exposure To Assertio Holdings

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”) announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have each recommended that Spectrum stockholders vote “FOR” the proposal to adopt the Agreement and Plan of Merger (“Merger Agreement”, and such proposal, the “Merger Proposal”) at the upcoming special meeting of stockholders (the “Speci.

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.

Assertio Therapeutics Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT). Under the terms of the proposed transaction, shareholders of Spectrum will receive, for each share of Spectrum that they own, 0.1783 shares of Assertio and one contingent value right for the right to receive $0.10 paya.

SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI

Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON has the potential to become the standard of care for reducing chemotherapy-induced neutropenia in a $3B domestic market. The combined companies of Assertio and Spectrum are estimated to provide a return of 4x.

Spectrum's Rolvedon A Differentiator In A $3B/Yr Market

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company previously receiv.

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.

Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update. First Quarter 2023 and Recent Business Update Net sales for Q1 2023 totaled $15.6 million, an increase of 54% compared to Q4 2022. 172 targeted accounts purchased ROLVEDON™ (eflapegrastim-xnst) Injection during the.

Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

ADiTx Therapeutics

Clover Health Investments

Novo Integrated Sciences, Inc.

OPKO Health

Senseonics Holdings

Tuya

Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1.10 To Watch This Week

Penny stocks to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Under $1.10 To Watch Now

NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals" or the "Company") (NASDAQ: SPPI), in connection with its acquisition by Assertio Holdings, Inc. (NASDAQ: ASRT) ("Assertio"). Under the merger agreement, the Company's shareholders will receive 0.1783 shares of Assertio common stock for each of their shares, representing implied per-share consideration of $0.89 based upon Assertio's April 26, 2023 closing price of $5.00.

SHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.

NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), in connection with its proposed merger with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum Pharmaceuticals"). If you own Assertio  shares  and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https://www.weisslaw.co/news-and-cases/asrt   Or please contact: Joshua Rubin, Esq.

SHAREHOLDER ALERT: Weiss Law Investigates Assertio Holdings, Inc.

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning.  The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.

Spectrum Pharmaceuticals stock pops after Assertio acquires it at a premium

MILWAUKEE , April 25, 2023 /PRNewswire/ -- Ademi LLP is investigating Spectrum (NASDAQ: SPPI) for possible breaches of fiduciary duty and other violations of law in its transaction with Assertio.  Click here to learn how to join the action https://www.ademilaw.com/case/spectrum-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Spectrum Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Assertio

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) to Assertio Holdings, Inc. is fair to Spectrum shareholders. Under the terms of the agreement, Spectrum shareholders will receive: (1) 0.1783 shares of Assertio common stock for each share of Spectrum common stock they own; and (2) one contingent value right per Spectrum share for the right to receive $0.10 payable upon ROLVEDON net sales (.

SPPI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Spectrum Pharmaceuticals, Inc. Is Fair to Shareholders

Spectrum Pharmaceuticals (NASDAQ: SPPI ) stock is soaring higher on Tuesday thanks to an acquisition deal with Assertio (NASDAQ: ASRT ). This deal will have Assertio acquire all outstanding shares of SPPI stock.

Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?

-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on gut-brain axis connection offers potential alternative to anti-psychotic treatments --

Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)

Bright Green Corp

Chembio Diagnostics

Healthcare Triangle

Hepion Pharmaceuticals Inc

Hillstream Biopharma

Magenta Therapeutics Inc

Sigilon Therapeutics

The healthcare sector has more high return generating companies than many other sectors.

10 Best-Performing Penny Stocks in the Health Care Sector

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Thomas Riga - President and Chief Executive Officer Michael Grabow - Executive Vice President and Chief Financial Officer Nora Brennan - Executive Vice President and Chief Financial Officer Erin Miller - Senior Vice President Sales and Marketing Conference Call Participants Maury Raycroft - Jefferies Edward White - H.C. Wainwright Reni Bennett Benjamin - JMP Securities Prakhar Agarwal - Cantor Fitzgerald Operator Good day and thank you for standing by.

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2022 Earnings Call Transcript

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 33.33% and 5.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Spectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m.

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

SelectQuote

Zhihu

Use these tips for taking profits with penny stocks The post How to Take Profits With Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Take Profits With Penny Stocks

Boxlight

Grove Collaborative Holdings

Imperial Petroleum

IronNet

Troika Media Group

VIQ Solutions

Virax Biolabs Group Ltd

GeneDx Holdings Corp

Wearable Devices Ltd

Penny stocks under $1 to watch this month. The post 10 Top Penny Stocks Under $1 To Watch For February 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks Under $1 To Watch For February 2023

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. “This is an important milestone in the ROLVEDON launch.

Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

News for Spectrum Pharma Stock (SPPI)